"
Accelerating Results in Clinical Trials Through Unified Technology Solutions"
|
LOCATION:
Terminal City Club, 837 West Hastings Street, Vancouver
|
|
LifeSciences BC Annual General Meeting 2019
|
DATE:
October 3
TIME:
8:00 AM
-
9:30 AM
LOCATION: Royal Bank Tower, 36th floor, 1055 West Georgia Street, Vancouver
AGENDA
8:00am: Continental Breakfast served
8:30am: Welcome remarks
8:35am: Annual General Meeting begins
9:30am: Annual General Meeting concludes
|
|
|
DATE:
October 7,2019
TIME:
8:00 AM
-
5:30 PM
LOCATION: Royal Bank Tower, 36th floor, 1055 West Georgia Street, Vancouver
AGENDA
Swedish Trade and Invest Council and the Embassy of Sweden are arranging a free digital health seminar in collaboration with the Ministry of Health in BC, Global Affairs Canada, RBC and LifeSciences BC to share challenges and opportunities but also showcase innovative Swedish and British Columbian digital health technologies.
|
|
Showcasing MedTech Innovations in Healthcare
|
DATE:
October 9,2019
TIME:
6.00PM - 8.00PM
LOCATION: McCarthy Tetrault LLP, 2400 - 745 Thurlow Street, Vancouver
Presenting
Companies:
- BioLytical Laboratories Inc.
Presentations
7:15 - 8:15pm - Wine & Appetizer Reception and Networking Opportunity
Tickets: LSBC member $25 and LSBC non-member $50
|
|
|
DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria
SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that on September 6, 2019, the Company was formally notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the applicable stockholders' equity requirement.
READ MORE
|
 |
ABCELLERA APPOINTS ANDREW BOOTH AS CHIEF FINANCIAL OFFICER AND TRYN STIMART AS GENERAL COUNSEL
Today AbCellera announced the expansion of its executive team with the hiring of Andrew Booth as Chief Financial Officer and Tryn Stimart as General Counsel. In his role as CFO, Andrew Booth will assume responsibility for corporate finance and growth, and as General Counsel, Tryn Stimart will oversee all corporate legal matters and lead AbCellera's intellectual property strategy.
READ MORE
|
|
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
BURLINGTON, Mass. and BURNABY, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) - Flexion Therapeutics, Inc. (Nasdaq:FLXN) and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) today announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain.
READ MORE
|
|
DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates
SAN DIEGO, Sept. 10, 2019 /PRNewswire/ -
DelMar Pharmaceuticals, Inc.
(Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended June 30, 2019.
READ MORE
|
DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019
SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -
DelMar Pharmaceuticals, Inc.
(Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that CEO Saiid Zarrabian will deliver a presentation on the Company and meet with investors at the Fall Investor Summit on September 16, 2019 at 1:30 PM ET in Track 1 at Essex House, 160 Central Park South in New York City. The conference is being held September 16-17, 2019.
READ MORE
|
Purdue inks multibillion-dollar opioid deal with thousands of local governments, more than 20 states: reports
|
Sep 11, 2019 | by
Eric Sagonowsky
|
Purdue Pharma has entered the first major opioid settlement. The company, whose OxyContin played a role in the opioid epidemic, plans to file for bankruptcy imminently and restructure under an agreement with 23 states and nearly 2,300 cities, counties and tribes,
according
to The New York Times.
READ MORE
|
|
Drug companies pay for exclusive access to UK genetic data
|
Four of the world's largest drug companies have agreed to pay around $120 million for exclusive access to genetic data on hundreds of thousands of people. Amgen, AstraZeneca, GlaxoSmithKline, and Johnson & Johnson will each have nine months to pour over the first wave of genomic data coming out of UK Biobank before the global research community gets a chance to look at it.
READ MORE
|
|
|
House Speaker Pelosi Seizes An Opening On Prescription Drug Prices
|
On Tuesday, a draft proposal from House Speaker Nancy Pelosi (D-California) leaked to the media. In it, Pelosi proposes that Medicare negotiate lower prescription drug prices using international prices as benchmarks, and that limits are imposed on out-of-pocket spending on drugs by Medicare beneficiaries.
READ MORE
|
|
CAR T-cell therapy may be harnessed to treat heart disease
Sept. 11th, 2019 |University of Pennsylvania School of Medicine | CAR T-cell therapy, a rapidly emerging form of immunotherapy using patients' own cells to treat certain types of cancers, may be a viable treatment option for another life-threatening condition: heart disease. Researchers at Penn Medicine used genetically modified T cells to target and remove activated fibroblasts that contribute to the development of cardiac fibrosis -- a scarring process found in most forms of heart disease that results in heart stiffness and decreased function of the heart. READ MORE
|
|
What are vaping-associated illnesses and why are doctors concerned?
Sep 12, 2019 | CBC Health News |
Health officials in the U.S. have flagged hundreds of serious respiratory illnesses among people who use e-cigarettes, including six deaths. For doctors in Canada, the sudden illness adds to their concerns that people wrongly assume vaping products are harmless.
READ MORE
|
approximately 60,000 visitors a month?
~
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings comes with a
free repost on Biotalent's
The Petri Dish?
After your first five reposts, you will also receive 25% off all job
postings on
The Petri Dish!
|
|
|
|
